Taxotere Will Benefit From "Average Sales Price" Reimbursement
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis expects Taxotere's performance in the U.S. to receive a boost from the implementation of "average sales price" reimbursement under Medicare in 2005
You may also be interested in...
A New Start: President Biden Visits Pfizer
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
US Pharma Faces First Drug Pricing Fight Of 2021
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.
Pazdur Unplugged: US FDA’s “Project Livin’ Label” Shows Back Story On Cancer Drug Approvals
Latest Oncology Center of Excellence initiative is officially a CME effort designed to encourage practitioners to make full use of the information in the approved drug labeling. It is also a surprisingly effective way to explain drug approvals in a flattering light for regulators and sponsors.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: